ADAM9: A novel player in vestibular schwannoma pathogenesis

Breun,Maria; Schwerdtfeger,Alexandra; Martellotta,Donato   Daniel; Kessler,Almuth  F.; Monoranu,Camelia  M.; Matthies,Cordula; Löhr,Mario; Hagemann,Carsten

doi:10.3892/ol.2020.11299

ADAM9: A novel player in vestibular schwannoma pathogenesis

Authors:
- Maria Breun
- Alexandra Schwerdtfeger
- Donato Daniel Martellotta
- Almuth F. Kessler
- Camelia M. Monoranu
- Cordula Matthies
- Mario Löhr
- Carsten Hagemann
View Affiliations

Affiliations: Department of Neurosurgery, University Hospital Würzburg, D-97080 Würzburg, Germany, Department of Neuropathology, Institute of Pathology, University of Würzburg, D-97080 Würzburg, Germany
Published online on: January 14, 2020 https://doi.org/10.3892/ol.2020.11299
Pages: 1856-1864
Copyright: © Breun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. To the best of our knowledge, the present study was the first to examine ADAM9 expression in vestibular schwannomas (VS) from patients with and without neurofibromatosis type 2 (NF2) and to associate the data with clinical parameters of the patients. The aim of the present study was to evaluate if ADAM9 could be used as prognostic marker or therapeutic target. ADAM9 mRNA and protein levels were measured in VS samples (n=60). A total of 30 of them were from patients with neurofibromatosis. Healthy peripheral nerves from autopsies (n=10) served as controls. ADAM9 mRNA levels were measured by PCR, and protein levels were determined by immunohistochemistry (IHC) and western blotting (WB). The Hannover Classification was used to categorize tumor extension and hearing loss. ADAM9 mRNA levels were 8.8‑fold higher in VS compared with in controls. The levels were 5.6‑fold higher in patients with NF2 and 12‑fold higher in patients with sporadic VS. WB revealed two mature isoforms of the protein, and according to IHC ADAM9 was mainly expressed by S100‑positive Schwann cells. There was a strong correlation between ADAM9 mRNA expression and the level of functional impairment (r~1, p=0.01). Particularly, the secreted isoform of ADAM9 was expressed in patients with higher hearing impairment. ADAM9 mRNA was overexpressed in the tumor samples relative to healthy vestibular nerves, and there was an association between higher ADAM9 expression levels and greater hearing impairment. Therefore, ADAM9 may be a prognostic marker for VS, and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.

View Figures

View References

1	Stemmer-Rachamimov AO, Louis DN, Gunnlaugur PN, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, et al: Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 64:3718–3724. 2004. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Ohgaki H, Wiestler OD and Cavenee WK: WHO Classification of tumours of the central nervous system. WHO/IARC Classification of tumours, 4th edition revised. 1:2016.
3	Lim SH, Ardern-Holmes S, McCowage G and de Souza P: Systemic therapy in neurofibromatosis type 2. Cancer Treat Rev. 40:857–861. 2014. View Article : Google Scholar : PubMed/NCBI
4	Hanemann CO: Magic but treatable? Tumours due to loss of merlin. Bain. 131:606–615. 2008.
5	Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, et al: Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients. J Med Genet. 52:699–705. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cooper J and Giancotti FG: Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett. 588:2743–2752. 2014. View Article : Google Scholar : PubMed/NCBI
7	Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z and Lonser RR: Neurofibromatosis type 2. Lancet. 373:1974–1986. 2009. View Article : Google Scholar : PubMed/NCBI
8	Schulz A, Zoch A and Morrison H: A neuronal function of the tumor suppressor protein merlin. Acta Neuropathol Commun. 2:822014. View Article : Google Scholar : PubMed/NCBI
9	Schulz A, Büttner R, Hagel C, Baader SL, Kluwe L, Salamon J, Mautner VF, Mindos T, Parkinson DB, Gehlhausen JR, et al: The importance of nerve microenvironment for schwannoma development. Acta Neuropathol. 132:289–307. 2016. View Article : Google Scholar : PubMed/NCBI
10	Duffy MJ, McKiernan E, O´Donovan N and McGowan PM: Role of ADAMs in cancer formation and progression. Clin cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
11	Klein T and Bischoff R: Active metalloproteases of the A disintegrin and metalloprotease (ADAM) family: Biological function and structure. J Proteome Res. 10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
12	Weskamp G, Kratzschmar J, Reid MS and Blobel CP: MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J Cell Biol. 132:717–726. 1996. View Article : Google Scholar : PubMed/NCBI
13	McKie N, Dallas DJ, Edwards T, Apperley JF, Russell RG and Croucher PI: Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. Biochem J. 318:459–462. 1996. View Article : Google Scholar : PubMed/NCBI
14	Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci. 98:621–628. 2007. View Article : Google Scholar : PubMed/NCBI
15	Fan X, Wang Y, Zhang C, Liu L, Yang S, Wang Y, Xing L, Qian Z, Fang S, Qiao H and Jiang T: ADAM9 expression is associated with glioma tumor grade and histological type, and acts as a prognostic factor in lower-grade gliomas. Int J Mol Sci. 17(pii): E12762016. View Article : Google Scholar : PubMed/NCBI
16	Huang CF, Yang SF, Chiou HL, Hsu WH, Hsu JC, Liu CJ and Hsieh YH: Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways. Food Funct. 9:6196–6204. 2018. View Article : Google Scholar : PubMed/NCBI
17	Oria VO, Lopatta P, Schmitz T, Preca BT, Nyström A, Conrad C, Bartsch JW, Kulemann B, Hoeppner J, Maurer J, et al: ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol Oncol. 13:456–479. 2019. View Article : Google Scholar : PubMed/NCBI
18	Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M and Toker A: A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 65:4728–4738. 2005. View Article : Google Scholar : PubMed/NCBI
19	Fry JL and Toker A: Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 70:8187–8198. 2010. View Article : Google Scholar : PubMed/NCBI
20	Qian LW, Mizumoto K, Urashima T, Nagai E, Maehara N, Sato N, Nakajima M and Tamaka M: Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res. 8:1223–1227. 2002.PubMed/NCBI
21	Mongaret C, Alexandre J, Thomas-Schoemann A, Bermudez E, Chéreau C, Nicco C, Goldwasser F, Weill B, Batteux F and Lemare F: Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. Int J Cancer. 129:791–798. 2011. View Article : Google Scholar : PubMed/NCBI
22	Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE and Chung LW: Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate. 67:722–731. 2007. View Article : Google Scholar : PubMed/NCBI
23	Breun M, Schwerdtfeger A, Martellotta DD, Kessler AF, Perez JM, Monoranu CM, Ernestus RI, Matthies C, Löhr M and Hagemann C: CXCR4: A new player in vestibular schwannoma pathogenesis. Oncotarget. 9:9940–9950. 2018. View Article : Google Scholar : PubMed/NCBI
24	Hsia HE, Tüshaus J, Brummer T, Zheng Y, Scilabra SD and Lichtenthaler SF: Functions of ‘A disintegrin and metalloproteases (ADAMs)’ in the mammalian nervous system. Cell Mol Life Sci. 76:3055–3081. 2019. View Article : Google Scholar : PubMed/NCBI
25	Wippold FJ II, Lubner M, Perrin RJ, Lämmle M and Perry A: Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns. AJNR Am J Neuroradiol. 28:1633–1638. 2007. View Article : Google Scholar : PubMed/NCBI
26	Samii M and Matthies C: Management of 1000 vestibular schwannomas (acoustic neuromas): Hearing function in 1000 tumor resections. Neurosurgery. 40:248–262. 1997. View Article : Google Scholar : PubMed/NCBI
27	Hummel M, Perez J, Hagen R, Gelbrich G, Ernestus RI and Matthies C: When does hearing loss occur in vestibular schwannoma surgery? Importance of auditory brainstem response changes in early postoperative phase. World Neurosurg. 95:91–98. 2016. View Article : Google Scholar : PubMed/NCBI
28	Moffat DA, Kasbekar A, Axon PR and Lloyd SK: Growth characteristics of vestibular schwannoma. Otol Neurotol. 33:1053–1058. 2012.PubMed/NCBI
29	Sughrue ME, Kane AJ, Kaur R, Barry JJ, Rutkowski MJ, Pitts LH, Cheung SW and Parsa AT: A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg. 114:381–385. 2011. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Oria VO, Lopatta P and Schilling O: The pleiotropic role of ADAM9 in the biology of solid tumors. Cell Mol Life Sci. 75:2291–2301. 2018. View Article : Google Scholar : PubMed/NCBI
32	Heit B, Tavener S, Raharjo E and Kubes P: An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol. 159:91–102. 2002. View Article : Google Scholar : PubMed/NCBI
33	Amendola RS, Martin AC, Selistre-de-Araújo HS, Paula-Neto HA, Saldanha-Gama R and Barja-Fidalgo C: ADAM9 disintegrin domain activates human neutrophils through an autocrine circuit involving integrins and CXCR2. J Leukoc Biol. 97:951–962. 2015. View Article : Google Scholar : PubMed/NCBI
34	Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, Mirabolfathinejad SG, Dickey BF, Zhou Q and Moghaddam SJ: Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer. 12:1542013. View Article : Google Scholar : PubMed/NCBI